Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Untitled source document

No live link available for this source.

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Buying any stock in Taiwan will make you money

    60% confidence
  • Taiwan's stock market is clearly overheated

    60% confidence
  • Many Taiwanese brokerages have hit their internal limits on certain types of loans and are demanding more collateral and raising rates

    60% confidence
  • Taiwan is regarded by contrarians as Exhibit A of the world's rapidly inflating AI bubble

    60% confidence
  • Taiwan is the world's No. 1 producer of chips that power AI technology

    60% confidence
  • Taiwan's stock market has rallied over 100% in the past year, making it the world's fifth largest market, overtaking the UK, Canada, and India

    60% confidence
  • Teenagers in Taiwan are rushing to open brokerage accounts amid the stock market frenzy

    60% confidence
  • A sudden, deep sell-off in Taiwan's stock market would trigger devastating losses for young investors who see equities as easy money

    60% confidence
  • The Taiwan Central Bank's June 3 debt auction failed to attract enough buyers — the first time that has ever happened

    60% confidence
  • Investors rebuffed by their brokers for margin loans turn to banks instead, taking out new loans or canceling financial products to free up cash for stock investing

    60% confidence
  • Taiwan's stock market is not a bubble

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com